论文部分内容阅读
据世界医药新闻杂志(Scrip)10月18日报道,欧洲制药协会(EAEPC)和欧委会(EuropeanCommission)日前联手将辉瑞公司告上法庭,状告其违反欧盟竞争法,实行双重价格体系,并阻碍西班牙向欧盟其它国家出口药品。诉状称辉瑞利用在西班牙药市的支配地位,将药品以高于与西班牙当局协议的价
According to the Scrip report on October 18, the European Pharmaceutical Association (EAEPC) and the European Commission recently joined forces to bring Pfizer to court, suing them for violating the EU competition law and implementing a dual pricing system. Hinder Spain’s exports to other EU countries. The complaint alleges that Pfizer used the dominance of the Spanish drug market to place the drug at a higher price than the agreement with the Spanish authorities